|
Samantha Tang, PhD; Natalie E. Anderson, PhD; Kate Faasse, PhD; William P. Adams Jr, MD; and Jill M. Newby, PhD Aesthetic Surgery Journal, sjab215 Background: Breast implant illness (BII) is a term used to describe physical and psychological symptoms experienced by some women following breast implant surgery. Few studies have examined the experiences of women with BII—a poorly understood condition with no clear cause or treatment.
>> View on the Aesthetic Surgery Journal Website
|
|
Marshall E. Kadin, MD; Haiying Xu, BA; Lisa M. Hunsicker, MD; and Yingjie Guan, MD, PhD
Aesthetic Surgery Journal, sjab215
Background: CD30 lymphocyte activation antigen and phosphorylated STAT3 (pSTAT3) are consistent markers of tumor cells in breast implant–associated anaplastic large cell lymphoma (BIA-ALCL). We present a case of BIA-ALCL in a breast implant capsule containing clustered tumor cells expressing CD30, pSTAT3, pSTAT6, interleukin 9, and granzyme B tumor cell biomarkers. Remarkably, the contralateral breast contained many scattered large, atypical CD30+ cells surrounded by inflammatory cells, raising a suspicion of bilateral BIA-ALCL, known to occur in some patients. To clarify the diagnosis, immunohistochemistry and multilabel immunofluorescence were performed. Unlike the tumor cells, the atypical CD30+ cells of the contralateral breast lacked pSTAT3, pSTAT6, interleukin 9, and granzyme B, eliminating a diagnosis of bilateral BIA-ALCL. This case highlights the importance of interpreting CD30 staining in the context of other tumor cell biomarkers and histopathology to avoid an incorrect diagnosis of BIA-ALCL. We believe the findings also suggest the possibility of CD30 expression as an early event in the multistep pathogenesis of BIA-ALCL. >> View on the Aesthetic Surgery Journal Website |
|
|
Marshall E Kadin, MD, John Morgan, PhD, Haiying Xu, BS, Caroline Glicksman, MD, David Sieber, MD, William P Adams, Jr, MD, Pat McGuire, MD, Mark W Clemens, MD, Archana Thakur, PhD, Lawrence G Lum, MD, DSc
Aesthetic Surgery Journal, sjaa302
Background: Granzyme B (GrB) is a serine protease secreted, along with pore-forming perforin, by cytotoxic lymphocytes to mediate apoptosis in target cells. GrB has been detected in tumor cells associated with systemic and breast implant–associated anaplastic large cell lymphoma (BIA-ALCL) but its potential use for detection of early BIA-ALCL has not been fully investigated.
>> View on the Aesthetic Surgery Journal Website |
|
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
|
|
Page 7 of 17 |
